Wonder Drug, Generic Price: What Semaglutide’s Patent Expiry Should Really Mean for India
[This post is co-authored with Khushi Krishania. Khushi is a third-year B.Sc. LL.B. (Hons.) {Cybersecurity} student at the National Law Institute University, Bhopal, with a particular interest in the intersection of copyright and data protection law.] Christmas came early for Indian generic manufacturers as the Indian patent on Semaglutide, a potent GLP-1 receptor agonist, expired on March 20. The drug is commercially sold by Novo Nordisk as Ozempic and Wegovy and is used to manage type-2 diabetes and obesity. After […]









